OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit


Ravindra K. Pandey

Ravindra K. Pandey

Roswell Park Cancer Institute


Dr. Ravindra K. Pandey, Distinguished Member, Professor of Oncology and Director of Pharmaceutical Chemistry at Roswell Park Cancer Institute is a trained synthetic medicinal chemist with extensive experience in drug design, drug delivery, molecular recognition, and tumor diagnostics. His research group has also been looking at the utility of nanoparticles (ORMOSIL, polyacrylamide, gold, rHDL, chitosan and certain polymers) in developing multifunctional platforms. Dr. Pandeyreceived NIH funding in all five areas and his program has been continuously funded by the federal and private organizations since 1992.One of the photosensitizers (HPPH) synthesized in his laboratory is currently undergoing Phase I/II human clinical trials and other two candidates which show potential for tumor imaging by PET and near infrared (NIR) fluorescence-guided photodynamic therapy (including surgery) are at advanced stages of preclinical studies. The current focus of his laboratory is to develop tumor-targeted dual-modality agents, multifunctional biodegradable/biocompatible nanoparticles for imaging and photodynamic therapy (PDT) in combination with other treatment modalities (e. g., surgery and chemotherapy). Efforts are also underway to isolate plant products from Indian and Chinese medicinal plants and investigate their biological efficacy. Dr. Pandey has published >250 research papers, several review articles, book chapters and has >40 patents to his credit. He has organized several national and international symposiums on PDT and tumor-imaging. He is the member of the Editorial and Advisory Board of several International Scientific Journals and reviewers of grant proposals of several countries, including the United States (NIH). Dr.Pandey has received western New York Inventor of the year awards (several),international award on heterocyclic chemistry, award for the excellence in PDT by an International Society of Porphyrins and Phthalocyanines and the American Chemical Society’s Jacob Schoelkopf award for his contribution in translational research. Dr. Pandey is the Founder and Chief Scientific Officer (CSO) of Photolitec, LLC, a spin-off company of Roswell Park Cancer Institute. His research is “truly” translational, and some of his inventions are already licensed to various pharmaceutical companies.